DISCOVER CIBINQO

One pill, once a day.
Not an injection or cream.
CIBINQO—a Pfizer innovation.

One pill, once a day.

Not an injection
or cream.

CIBINQO—a Pfizer
innovation.

  • CIBINQO (si-BINK-oh) is 100% steroid free
  • It's a different kind of treatment called a JAK inhibitor that blocks the JAK1 protein, and is thought to reduce inflammation
  • Those studied were determined to have moderate-to-severe eczema based on itch and signs of eczema on their skin
  • Some people took only CIBINQO and some took a placebo (unmedicated treatment). In one study, people took either CIBINQO with topical steroids or placebo with topical steroids. People were able to use a moisturizer in the studies
  • Some studies focused on effectiveness and safety over 3 or 4 months, and measured skin improvement, skin clearance, and itch reduction
  • People who completed a short-term study were able to enter a long-term study focused on safety
  • While people 12 to 17 years old were included in some of the studies, CIBINQO is not approved for use in pediatric patients
Steroid Lady
Results showed

After 3 months on CIBINQO 100 mg

after eczema on abdomen

Before CIBINQO

before eczema on abdomen

Photos of a patient's abdomen. Patient took CIBINQO along with over-the-counter moisturizer. Not everyone will respond to treatment with CIBINQO.

After 3 months on CIBINQO 100 mg

after eczema on upper arm

Before CIBINQO

before eczema on upper arm

Close-up photos of a patient's upper arm. Not everyone will respond to treatment with CIBINQO.

After 3 months on CIBINQO 200 mg

after eczema on abdomen 1

Before CIBINQO

before eczema on abdomen 1

Close-up photos of a patient's abdomen. Not everyone will respond to treatment with CIBINQO.

After 3 months on CIBINQO 200 mg

after eczema on calf

Before CIBINQO

before eczema on calf

Close-up photos of a patient's calf. Not everyone will respond to treatment with CIBINQO.

After 3 months on CIBINQO 100 mg

after eczema on lower shin

Before CIBINQO

before eczema on lower shin

Photos of a patient's lower shin. Not everyone will respond to treatment with CIBINQO.

After 3 months on CIBINQO 200 mg

after eczema on lower chest and abdomen

Before CIBINQO

before eczema on lower chest and abdomen

Photos of a patient's lower chest and abdomen. Patient took CIBINQO with topical steroid treatment and over-the-counter moisturizer. In a study of 837 people, more people taking CIBINQO with topical steroids and daily moisturizer achieved clear or almost clear skin at 3 months (36% on 100 mg and 47% on 200 mg) vs people taking placebo with topical steroids and daily moisturizer (14%). Not everyone will respond to treatment with CIBINQO.

After
3 months on CIBINQO 100 mg

after eczema on abdomen

Before
CIBINQO

before eczema on abdomen

Photos of a patient's abdomen. Patient took CIBINQO along with over-the-counter moisturizer. Not everyone will respond to treatment with CIBINQO.

After
3 months on CIBINQO 100 mg

after eczema on upper arm

Before
CIBINQO

before eczema on upper arm

Close-up photos of a patient's upper arm. Not everyone will respond to treatment with CIBINQO.

After
3 months on CIBINQO 200 mg

after eczema on abdomen 1

Before
CIBINQO

before eczema on abdomen 1

Close-up photos of a patient's abdomen. Not everyone will respond to treatment with CIBINQO.

After
3 months on CIBINQO 200 mg

after eczema on calf

Before
CIBINQO

before eczema on calf

Close-up photos of a patient's calf. Not everyone will respond to treatment with CIBINQO.

After
3 months on CIBINQO 100 mg

after eczema on lower shin

Before
CIBINQO

before eczema on lower shin

Photos of a patient's lower shin. Not everyone will respond to treatment with CIBINQO.

After
3 months on CIBINQO 200 mg

after eczema on lower chest and abdomen

Before
CIBINQO

before eczema on lower chest and abdomen

Photos of a patient's lower chest and abdomen. Patient took CIBINQO with topical steroid treatment and over-the-counter moisturizer. In a study of 837 people, more people taking CIBINQO with topical steroids and daily moisturizer achieved clear or almost clear skin at 3 months (36% on 100 mg and 47% on 200 mg) vs people taking placebo with topical steroids and daily moisturizer (14%). Not everyone will respond to treatment with CIBINQO.

before and after eczema on abdomen
before and after eczema on upper arm
before-and-after eczema on abdomen 1
before and after eczema on calf
before and after eczema on lower shin
before and after eczema on lower chest and abdomen
Pfizer Dermatology Patient Access Logo
savings card
savings & support icon 2
A live Support Representative can help you understand coverage and explore financial assistance options. Call 1-833-956-DERM (1-833-956-3376) Mon-Fri, 8 AM-8 PM EST, or ask your doctor’s office.
interim care program icon
Pfizer Dermatology Patient Access can help if your insurance delays or denies coverage of CIBINQO. Eligible, commercially insured patients enrolled in the Interim Care program may receive CIBINQO for up to 2 years at no cost.

auto

Talk to your doctor about CIBINQO

Ready to ask your doctor about CIBINQO? Get tips and download our Doctor Discussion Guide to help start the conversation.

Pfizer Dermatology Patient Access Logo 1

A personalized savings and support program

Learn more about financial assistance options and other resources by talking to a Patient Support Representative.

patient support representative

Call 1-833-956-DERM (1-833-956-3376)
Monday-Friday, 8:00 AM-8:00 PM ET

You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only).
If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

You are encouraged to report adverse events related to Pfizer products by calling
1-800-438-1985 (U.S. only).

If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

CIBINQO may cause serious side effects, including:

Serious infections. CIBINQO can lower your immune system’s ability to fight infections. Do not start CIBINQO if you have any kind of infection unless your healthcare provider tells you it is okay. Serious infections, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body, have occurred in people taking CIBINQO or other similar medicines. Some people have died from these infections. Your risk of developing shingles may increase while taking CIBINQO.

Your healthcare provider should test you for TB before treatment with CIBINQO and monitor you closely for signs and symptoms of TB infection during treatment.

Before and after starting CIBINQO, tell your doctor right away if you have an infection, are being treated for one, or have symptoms of an infection, including:

  •  
  • fever, sweating, or chills
  • muscle aches
  • cough or shortness of breath
  • blood in your phlegm
  • weight loss
  • warm, red, or painful skin or sores on your body
  • diarrhea or stomach pain
  • burning when you urinate or urinating more often than usual
  • feeling very tired
  •  

CIBINQO can make you more likely to get infections or worsen infections you have.

There is an increased risk of death in people 50 years and older who have at least one heart disease (cardiovascular) risk factor and are taking a Janus kinase (JAK) inhibitor (such as CIBINQO).

Cancer and immune system problems. CIBINQO may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. People, especially current or past smokers, have a higher risk of certain cancers, including lymphoma and lung cancers, while taking a JAK inhibitor. Follow your healthcare provider’s advice about having your skin checked for skin cancer during treatment. Limit the amount of time you spend in sunlight and avoid using tanning beds or sunlamps. When in the sun, wear protective clothing and use SPF 30+ sunscreen. This is especially important if you have very fair skin or a family history of skin cancer. Tell your healthcare provider if you have ever had any type of cancer.

There is an increased risk of major cardiovascular (CV) events such as heart attack, stroke or death in people 50 years and older who have at least one heart disease (CV) risk factor and are taking a JAK inhibitor, especially for current or past smokers.

Some people taking CIBINQO have had major cardiovascular events.

Get emergency help right away if you develop any symptoms of a heart attack or stroke while taking CIBINQO, including:

  • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw, or stomach
  • weakness in one part or on one side of your body
  • slurred speech
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded

Blood clots. Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking CIBINQO. This may be life-threatening. Blood clots in the veins of the legs and lungs have happened more often in people 50 years and older, with at least one heart disease (CV) risk factor, taking a JAK inhibitor. Tell your healthcare provider if you have had blood clots in the veins of your legs or lungs in the past.

Get medical help right away if you have any signs and symptoms of blood clots including swelling, pain, or tenderness in one or both legs; sudden, unexplained chest or upper back pain; shortness of breath or difficulty breathing.

Changes in certain laboratory test results. Your doctor should do blood tests before and during treatment with CIBINQO to check your lymphocyte, neutrophil, red blood cell, and platelet counts. You should not take CIBINQO if these counts are too low. Your healthcare provider may stop treatment for a period of time if there are changes in these blood test results. You may also have changes in other laboratory tests, such as your blood cholesterol levels. Your doctor should do blood tests about 4 weeks after you start treatment and 4 weeks after any increase in dose to check blood cell counts and as often as needed for other laboratory tests.

During the first 3 months of treatment with CIBINQO, do not take medicines that prevent blood clots except low-dose aspirin (≤81 mg daily), if prescribed.

Before taking CIBINQO, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have one that won't go away or keeps returning
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have TB or have been in close contact with someone with TB
  • have had shingles (herpes zoster)
  • have had hepatitis B or hepatitis C
  • live, have lived, or traveled to certain areas (such as Ohio & Mississippi River Valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or worsen when taking CIBINQO. Ask your healthcare provider if you're unsure if you have lived in an area where these infections are common
  • have had any type of cancer
  • have had blood clots in the veins of your legs or lungs
  • are a current or past smoker
  • have had a heart attack, other heart problems, or stroke
  • have kidney or liver problems
  • have abnormal blood tests (low platelet count or white blood cell count)
  • have any eye problems, including cataracts or retinal detachment
  • have recently received or are scheduled to receive any vaccinations. People who take CIBINQO should not receive live vaccines
  • are or plan to become pregnant. It is not known if CIBINQO will harm your unborn baby. Pfizer has a Pregnancy Exposure Registry for pregnant women who take CIBINQO to check your health and the health of your baby. If you are pregnant or become pregnant while taking CIBINQO, ask your healthcare provider how you can join this pregnancy registry or call 1-877-311-3770 to enroll
  • are breastfeeding or plan to breastfeed. It is not known if CIBINQO passes into your breast milk. You should not take CIBINQO while breastfeeding
  • are taking other medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. CIBINQO and other medicines may affect each other, causing side effects. Especially tell your healthcare provider if you take aspirin or any antiplatelet therapies. Ask your healthcare provider if you are unsure



The most common side effects of CIBINQO include common cold, nausea, headache, herpes simplex including cold sores, increased blood level of creatinine phosphokinase, dizziness, urinary tract infection, tiredness, acne, vomiting, mouth and throat pain, flu, stomach flu, bacterial skin infection, high blood pressure, allergic skin rash to something you contacted, stomach pain, shingles, and low platelet count.

CIBINQO may cause fertility problems in females, which may affect the ability of females to get pregnant. Talk to your healthcare provider if you have concerns about fertility.

Separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people treated with CIBINQO. Call your healthcare provider right away if you have any sudden changes in your vision.

These are not all of the possible side effects of CIBINQO.

What is CIBINQO?

CIBINQO is a prescription medicine to treat adults with moderate-to-severe eczema (atopic dermatitis) that did not respond to other treatment and is not well controlled with prescription medicines, including biologics, or when they cannot be tolerated.

It is not known if CIBINQO is safe and effective in children.

Please see full Prescribing Information, including BOXED WARNING, and Medication Guide.

Pfizer logo
Pfizer logo

Pfizer Dermatology Patient Access Interim Care Rx Program
TERMS AND CONDITIONS

×
Interim Care Rx is not health insurance and is available for eligible, commercially insured patients only. Offer is only available to patients who have been diagnosed with an FDA-approved indication for CIBINQO™ (abrocitinib). No claim for reimbursement for product dispensed pursuant to this offer may be submitted to any third-party payer. Not available to patients covered under Medicaid, Medicare or other federal or state healthcare programs, including any state prescription drug assistance programs and the Government Health Insurance Plan or for residents of Massachusetts, Michigan, Minnesota, Missouri, Ohio, or Rhode Island. Available up to a 30-day supply. Refills are subject to limitations. Interim Care Rx offer does not require, nor will be made contingent on, purchase requirements of any kind. Pfizer reserves the right to amend, rescind, or discontinue this program at any time without notification. Interim Care Rx can only be dispensed by the exclusive pharmacy and only after benefits investigation has been completed and a delay occurs in the prior authorization or appeals process. Offer good only in the U.S. and Puerto Rico. Prescription must be provided by a healthcare provider licensed in the U.S. or Puerto Rico. Continued eligibility for the program requires submission of two appeals within 180 days of enrollment. After 12 months of program enrollment, an updated prescription and benefits investigation is required to confirm continued eligibility. Additional eligibility criteria may apply. Contact Pfizer Dermatology Patient Access™ at
1-833-956-3376 for details.